Analysts Set Insmed, Inc. (NASDAQ:INSM) Target Price at $209.35

Insmed, Inc. (NASDAQ:INSM) has been given an average recommendation of “Buy” by the twenty-six ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, twenty-three have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $205.2609.

INSM has been the topic of a number of analyst reports. UBS Group reiterated a “buy” rating and set a $172.00 price objective on shares of Insmed in a research note on Friday. Royal Bank Of Canada dropped their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Roth Capital reiterated a “buy” rating on shares of Insmed in a research report on Monday, June 8th. Guggenheim reduced their price target on shares of Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a research report on Friday. Finally, BMO Capital Markets started coverage on shares of Insmed in a research note on Monday, July 20th. They issued an “outperform” rating and a $192.00 price objective on the stock.

Insiders Place Their Bets

In other news, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the completion of the transaction, the chief executive officer owned 259,058 shares of the company’s stock, valued at approximately $30,413,409.20. The trade was a 3.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Sara Bonstein sold 2,404 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the sale, the chief financial officer owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This represents a 3.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 54,590 shares of company stock worth $5,793,738. 2.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insmed

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after purchasing an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. grew its stake in shares of Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after buying an additional 475,832 shares during the last quarter. State Street Corp increased its holdings in shares of Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after buying an additional 1,217,390 shares in the last quarter. RTW Investments LP increased its holdings in shares of Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after buying an additional 1,758,321 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Insmed by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after acquiring an additional 539,625 shares in the last quarter.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Insmed Price Performance

NASDAQ:INSM opened at $131.10 on Thursday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The firm has a market cap of $28.42 billion, a price-to-earnings ratio of -31.90 and a beta of 0.81. The firm’s 50-day simple moving average is $105.14 and its 200 day simple moving average is $129.23. Insmed has a 52 week low of $90.39 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative return on equity of 122.43% and a negative net margin of 76.94%.The firm had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. During the same period in the previous year, the firm earned ($1.70) EPS. The company’s quarterly revenue was up 296.1% compared to the same quarter last year. As a group, sell-side analysts predict that Insmed will post -2.37 earnings per share for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.